{"url_path":"/sec/cgtx/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-064863-index.html","accession_number":"0001104659-26-064863","cik":"0001455365","ticker":"CGTX","issuer_name":"COGNITION THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-064863-index.html","primary_entity_key":"0001455365","primary_entity_name":"COGNITION THERAPEUTICS INC"},"word_count":59,"has_tables":true,"body_markdown":"**Item 8.01 Other Events.**\n\n \n\nOn May 21, 2026,\nCognition Therapeutics, Inc. (the “Company”) issued a press release announcing the completion of its meeting with the\nU.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies patients with psychosis. A copy of the Company’s\npress release is filed as Exhibit 99.1 to this Current Report on Form 8-K."}